Exchange: NASDAQ·Updated 07:30 PM EST

RNA News

News
all
press releases
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Atrium Therapeutics Reports Third Quarter 2026 Financial Results Atrium Therapeutics Reports Third Quarter 2026 Financial ResultsPR NewswireSAN DIEGO, Nov. 12, 2026 -- First patient dosed with ATR 1072 in the Corventis Phase 1/2 clinical trial in PRKAG2 syndrome ---- Nonclinical data showed ATR...
PR Newswire
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Atrium Therapeutics Reports Third Quarter 2026 Financial Results Atrium Therapeutics Reports Third Quarter 2026 Financial ResultsPR NewswireSAN DIEGO, Nov. 12, 2026 -- First patient dosed with ATR 1072 in the Corventis Phase 1/2 clinical trial in PRKAG2 syndrome ---- Nonclinical data showed ATR...
PR Newswire
More News
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA...
PR Newswire
Atrium Therapeutics Doses First Patient in Corventis, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome Atrium Therapeutics Doses First Patient in Corventis, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromePR NewswireSAN DIEGO, Oct. 27...
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Oct. 20, 2026 SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingPR NewswireWESTPORT, Conn., Oct...
PR Newswire
Atrium Therapeutics Announces $50 Million Private Placement Atrium Therapeutics Announces $50 Million Private PlacementPR NewswireSAN DIEGO, Oct. 8, 2026SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing...
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Sept. 21, 2026 SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics to Participate in Upcoming Investor Conferences Atrium Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), abiopharmaceutical company advancing...
PR Newswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Aug. 20, 2026 SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics Reports Second Quarter 2026 Financial Results Atrium Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment...
PR Newswire

Advertisement|Remove ads.